chrX-154411856-G-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM1
The NM_000116.5(TAFAZZIN):c.13G>T(p.Val5Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000159 in 1,197,370 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 2 hemizygotes in GnomAD. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000018 ( 0 hom., 1 hem., cov: 24)
Exomes 𝑓: 0.000016 ( 0 hom. 1 hem. )
Consequence
TAFAZZIN
NM_000116.5 missense
NM_000116.5 missense
Scores
8
4
5
Clinical Significance
Conservation
PhyloP100: 6.63
Genes affected
TAFAZZIN (HGNC:11577): (tafazzin, phospholipid-lysophospholipid transacylase) This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
DNASE1L1 (HGNC:2957): (deoxyribonuclease 1 like 1) This gene encodes a deoxyribonuclease protein that shows high sequence similarity to DNase I. The encoded protein is localized to the endoplasmic reticulum and modified by N-linked glycosylation. Alternate transcriptional splice variants encoding the same protein have been observed. [provided by RefSeq, Jan 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM1
In a chain Tafazzin (size 261) in uniprot entity TAZ_HUMAN there are 37 pathogenic changes around while only 4 benign (90%) in NM_000116.5
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TAFAZZIN | NM_000116.5 | c.13G>T | p.Val5Leu | missense_variant | 1/11 | ENST00000601016.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TAFAZZIN | ENST00000601016.6 | c.13G>T | p.Val5Leu | missense_variant | 1/11 | 1 | NM_000116.5 |
Frequencies
GnomAD3 genomes AF: 0.0000178 AC: 2AN: 112372Hom.: 0 Cov.: 24 AF XY: 0.0000290 AC XY: 1AN XY: 34538
GnomAD3 genomes
AF:
AC:
2
AN:
112372
Hom.:
Cov.:
24
AF XY:
AC XY:
1
AN XY:
34538
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000339 AC: 5AN: 147643Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 47991
GnomAD3 exomes
AF:
AC:
5
AN:
147643
Hom.:
AF XY:
AC XY:
0
AN XY:
47991
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000157 AC: 17AN: 1084998Hom.: 0 Cov.: 31 AF XY: 0.00000281 AC XY: 1AN XY: 356184
GnomAD4 exome
AF:
AC:
17
AN:
1084998
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
356184
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000178 AC: 2AN: 112372Hom.: 0 Cov.: 24 AF XY: 0.0000290 AC XY: 1AN XY: 34538
GnomAD4 genome
AF:
AC:
2
AN:
112372
Hom.:
Cov.:
24
AF XY:
AC XY:
1
AN XY:
34538
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
2
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 07, 2011 | Variant classified as Uncertain Significance - Favor Pathogenic. The Val5Leu var iant has not been reported in the literature but has been identified in an Ashke nazi Jewish individual with mild DCM and muscle weakness as well as two family m embers (brother and mother) with similar features. The variant was absent from 332 Ashkenazi Jewish control chromosomes, which is consistent with a pathogenic role (LMM unpublished data). Valine (Val) at position 5 is conserved across mamm als and amphibians, but is not 100% conserved across more evolutionary distant s pecies (fruitfly and yeast), reducing the likelihood that the change is pathogen ic. Valine and Leucine have similar biochemical properties, which also suggest t hat the change may not severely affect the protein. However, most TAZ variants a re pathogenic and cause Barth syndrome (www.barthsyndrome.org). In summary, thi s variant likely causes or contributes to disease but additional data is needed to establish this with certainty. Please note that a new biochemical test is ava ilable that can help establish a diagnosis of Barth syndrome (see recommendation s section). - |
3-Methylglutaconic aciduria type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 16, 2022 | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 5 of the TAZ protein (p.Val5Leu). This variant is present in population databases (rs397515737, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with TAZ-related conditions. ClinVar contains an entry for this variant (Variation ID: 42253). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 17, 2017 | A variant of uncertain significance has been identified in the TAZ gene. The V5L variant has not been published as pathogenic or been reported as benign to our knowledge. However, it is classified as a variant of uncertain significance in ClinVar by a different clinical laboratory, where it was observed in an Ashkenazi Jewish individual with mild DCM and muscle weakness, and segregated with similar features in this individual's mother and brother (ClinVar SCV000058726.4; Landrum et al., 2016). The V5L variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). Additionally, this substitution occurs at a position that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. Nevertheless, the V5L variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Furthermore, this variant lacks observation in a significant number of affected individuals, large segregation studies, and functional evidence, which would further clarify its pathogenicity. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 10, 2021 | The p.V5L variant (also known as c.13G>T), located in coding exon 1 of the TAZ gene, results from a G to T substitution at nucleotide position 13. The valine at codon 5 is replaced by leucine, an amino acid with highly similar properties. Based on data from gnomAD, the T allele has an overall frequency of 0.00387% (5/147643) total alleles studied, with 0 hemizygote(s) observed. The highest observed frequency was 0.07389% (5/6767) of Ashkenazi Jewish alleles. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
.;.;.;.;.;T;.;T
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;.;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
.;L;L;.;L;L;.;.
MutationTaster
Benign
D;D;D;D;D;D;D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Benign
.;.;N;.;.;.;N;N
REVEL
Pathogenic
Sift
Uncertain
.;.;D;.;.;.;T;T
Sift4G
Benign
T;T;T;T;T;T;T;T
Polyphen
1.0, 0.83, 0.98, 1.0
.;D;P;.;D;D;.;.
Vest4
0.48, 0.49, 0.50, 0.39, 0.53
MutPred
Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);Gain of catalytic residue at V5 (P = 0.0346);
MVP
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at